Abstract
As an interface with the environment, the skin is a complex ecosystem colonized by many microorganisms that coexist in an established balance. The cutaneous microbiome inhibits colonization with pathogens, such as Staphylococcus aureus, and is a crucial component for function of the epidermal barrier. Moreover, crosstalk between commensals and the immune system is now recognized because microorganisms can modulate both innate and adaptive immune responses. Host-commensal interactions also have an effect on the developing immune system in infants and, subsequently, the occurrence of diseases, such as asthma and atopic dermatitis (AD). Later in life, the cutaneous microbiome contributes to the development and course of skin disease. Accordingly, in patients with AD, a decrease in microbiome diversity correlates with disease severity and increased colonization with pathogenic bacteria, such as S aureus. Early clinical studies suggest that topical application of commensal organisms (eg, Staphylococcus hominis or Roseomonas mucosa) reduces AD severity, which supports an important role for commensals in decreasing S aureus colonization in patients with AD. Advancing knowledge of the cutaneous microbiome and its function in modulating the course of skin disorders, such as AD, might result in novel therapeutic strategies.
Original language | English (US) |
---|---|
Pages (from-to) | 26-35 |
Number of pages | 10 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 143 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
Funding
Disclosure of potential conflict of interest: A. S. Paller is an investigator without personal compensation for AbbVie, Anaptysbio, Eli Lilly, Galderma, Incyte, Leo, Janssen, Novartis, and Sanofi-Regeneron and a consultant with honorarium for AbbVie, Amgen, Asana, Dermavant, Dermira, Galderma, Eli Lilly, Forte, Leo, Matrisys, Menlo, Morphosys/Galapagos, Novartis, Pfizer, and Sanofi-Regeneron. A. D. Irvine reports personal fees from AbbVie, Dermavant, Pfizer, Sanofi-Regeneron, AbbVie, and Eli Lilly and grants from Abbvie and Sanofi-Regeneron outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
Keywords
- Atopic dermatitis
- Staphylococcus aureus
- biotherapy
- commensal
- host-microbiome interaction
- immune regulation
- microbiome
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology